IRONWOOD PHARMACEUTICALS INC
No enriched coverage for $IRWD in the last 7 days.
No SEC Form 4 filings for $IRWD in the last 30 days.
See all $IRWD insider activity →Ironwood Pharmaceuticals (IRWD) reported Q2 2026 results on an earnings call. LINZESS U.S. net sales were $282.3M, up 14% YoY, and full-year guidance was raised to $1.15B-$1.20B. Total revenue was $113.0M, adjusted EBITDA $83.0M, and GAAP net income $51.3M. The company also discussed STARS-2 and balance sheet actions, including $200M convertible note repayment.
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results – Raises full-year 2026 LINZESS ® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase
Ironwood Pharmaceuticals (IRWD) appointed Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, effective July 20, 2026, replacing retiring Dr. Michael Shetzline, who will advise during transition. IRWD said its confirmatory Phase 3 STARS-2 trial of apraglutide for SBS-IF began in June and is actively recruiting. IRWD shares last traded at $4.08, down 3.09%.
Recent IRWD coverage spans financial news, earnings and technology.
Guidance raise and balance-sheet actions (retired $200M convertibles) likely support near-term sentiment, while STARS-2 ramp and demand softening risk remain key swing factors.
Guidance upside plus active STARS-2 recruitment and $200M convertible note repayment are likely to support near-term sentiment and valuation.
Leadership change plus active Phase 3 recruitment can improve execution confidence for apraglutide in SBS-IF, supporting near-term sentiment while leaving efficacy/readout risk unchanged.
This is a routine insider open-market sale under a pre-arranged 10b5-1 plan, with limited direct signal value.
Share-authorization increase via equity plan amendment can modestly affect dilution expectations and equity compensation overhang.
alphai scores every news story that mentions IRWD with an AI model for sentiment and relevance, and aggregates insider trades from IRONWOOD PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ironwood Pharmaceuticals (IRWD) reported Q2 2026 results on an earnings call. LINZESS U.S. net sales were $282.3M, up 14% YoY, and full-year guidance was raised to $1.15B-$1.20B. Total revenue was $113.0M, adjusted EBITDA $83.0M, and GAAP net income $51.3M. The company also discussed STARS-2 and balance sheet actions, including $200M convertible note repayment.
6 min readIRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results – Raises full-year 2026 LINZESS ® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase
4 min readIronwood Pharmaceuticals (IRWD) appointed Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, effective July 20, 2026, replacing retiring Dr. Michael Shetzline, who will advise during transition. IRWD said its confirmatory Phase 3 STARS-2 trial of apraglutide for SBS-IF began in June and is actively recruiting. IRWD shares last traded at $4.08, down 3.09%.
3 min readSilver Ronald (PFO & PAO) sold 127,890 shares of IRONWOOD PHARMACEUTICALS INC (IRWD) at $4.52 ($0.58M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
1 min readIRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001446847 0001446847 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
4 min readWells Fargo increased its price target for Ironwood Pharmaceuticals (NASDAQ: IRWD) to $5.00 from $3.00, maintaining an "Equal Weight" rating. This adjustment follows Ironwood's strong guidance for its drug Linzess in fiscal year 2026, projected to achieve U.S. net sales of $1.125 billion to $1.175 billion, driven by pricing tailwinds amid a strategic list price reduction. Despite the positive outlook and other recent developments including a settlement with Ferring International and a Citizens upgrade, Wells Fargo remains cautious, emphasizing the critical importance of Apra's success for the stock's future performance.
3 min readIronwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
5 min readIronwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.
3 min readIronwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.
3 min readIronwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.
3 min read
